Tuesday, July 23, 2024 12:08:51 PM
"Elite Pharmaceuticals' shares have outperformed the Zacks Medical – Drugs industry over the past two years (+302.3% vs. -16.8%). The Zacks analyst believes that the successful commercial launch of the company's Elite label product line, efficient cost management, robust product pipeline (including methotrexate), strategic partnerships, and financial prudence position it for sustained growth."
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
Recent MIRA News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/25/2024 08:01:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/21/2024 11:00:15 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/27/2024 09:20:15 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 09/27/2024 08:45:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/12/2024 08:30:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 08:01:33 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 09/06/2024 08:38:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/05/2024 12:20:12 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/30/2024 08:05:09 PM
- IBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without Astronauts • IH Market News • 08/26/2024 12:58:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 08:15:12 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 08/16/2024 08:05:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:06:29 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/12/2024 12:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:13:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 12:54:37 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/26/2024 08:55:26 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 07/26/2024 08:49:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 08:07:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 09:12:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 09:00:40 PM
- MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing • PR Newswire (US) • 06/24/2024 12:30:00 PM
- Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year • PR Newswire (US) • 06/10/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 10:00:06 PM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM